Share on StockTwits

AstraZeneca plc (LON:AZN)‘s stock had its “market perform” rating reaffirmed by equities research analysts at Sanford C. Bernstein in a research note issued to investors on Wednesday. They currently have a GBX 4,400 ($74.69) price target on the stock. Sanford C. Bernstein’s target price indicates a potential upside of 0.78% from the company’s current price.

AstraZeneca plc (LON:AZN) opened at 4396.00 on Wednesday. AstraZeneca plc has a 52 week low of GBX 3028.50 and a 52 week high of GBX 5750.00. The stock’s 50-day moving average is GBX 4480.97 and its 200-day moving average is GBX 3989.67. The company’s market cap is £55.434 billion.

A number of other firms have also recently commented on AZN. Analysts at Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Monday. Separately, analysts at Societe Generale reiterated a “sell” rating on shares of AstraZeneca plc in a research note on Friday, June 13th. They now have a GBX 3,720 ($63.15) price target on the stock. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Friday, June 13th. They now have a GBX 3,950 ($67.05) price target on the stock. Seven analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. AstraZeneca plc has an average rating of “Hold” and an average target price of GBX 4,050.04 ($68.75).

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.